(0.29%) 5 146.50 points
(0.29%) 38 554 points
(0.41%) 17 919 points
(-0.79%) $83.19
(2.03%) $1.962
(-0.27%) $2 340.90
(0.98%) $27.52
(0.49%) $926.60
(-0.25%) $0.932
(-0.19%) $11.00
(-0.33%) $0.798
(0.55%) $92.38
@ $13.37
Išleistas: 14 vas. 2024 @ 21:08
Grąža: 11.41%
Ankstesnis signalas: vas. 13 - 17:35
Ankstesnis signalas:
Grąža: 0.00 %
Live Chart Being Loaded With Signals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States...
Stats | |
---|---|
Šios dienos apimtis | 772 159 |
Vidutinė apimtis | 1.34M |
Rinkos kapitalizacija | 1.75B |
EPS | $0 ( 2024-03-20 ) |
Kita pelno data | ( $0.340 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 23.63 |
ATR14 | $0.00800 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Tierney David S | Buy | 25 000 | Common stock, par value $0.001 per share |
2024-04-08 | Tierney David S | Sell | 25 000 | Common stock, par value $0.001 per share |
2024-04-08 | Tierney David S | Buy | 25 000 | Options to purchase common stock |
2024-03-27 | Elsbernd Brian | Sell | 25 000 | Common stock, par value $0.001 per share |
2024-02-15 | Del Carmen Jeffrey | Sell | 10 667 | Restricted Stock Units |
INSIDER POWER |
---|
37.04 |
Last 100 transactions |
Buy: 3 182 900 | Sell: 1 448 545 |
Tūris Koreliacija
Catalyst Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
PMTS | 0.897 |
KPTI | 0.88 |
AVID | 0.873 |
PRAA | 0.854 |
FCCO | 0.852 |
BNIXU | 0.849 |
PINC | 0.848 |
KTCC | 0.844 |
PARA | 0.843 |
DTEA | 0.838 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
CVGI | -0.927 |
CRSP | -0.915 |
NNOX | -0.915 |
POWL | -0.914 |
ADMS | -0.914 |
FTDR | -0.912 |
MDXG | -0.912 |
FLGC | -0.905 |
CNCE | -0.905 |
RESN | -0.904 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Catalyst Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Catalyst Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $398.20M |
Bruto pelnas: | $313.67M (78.77 %) |
EPS: | $0.670 |
FY | 2023 |
Pajamos: | $398.20M |
Bruto pelnas: | $313.67M (78.77 %) |
EPS: | $0.670 |
FY | 2022 |
Pajamos: | $214.20M |
Bruto pelnas: | $179.81M (83.94 %) |
EPS: | $0.800 |
FY | 2021 |
Pajamos: | $140.83M |
Bruto pelnas: | $118.95M (84.46 %) |
EPS: | $0.380 |
Financial Reports:
No articles found.
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.